Voriconazole
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Voriconazole
Voriconazole: Known uses and market status in Australia
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Voriconazole, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use among the candidates is recorded only as a knowledge graph relation, not as an approved indication.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| fusariosis |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10168E | Vfend | Powder for oral suspension 40 mg per mL, | Valid |
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): long QT syndrome (including familial), torsades de pointes, liver disease, gallbladder disease, potassium deficiency, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disorders, impaired renal function, vision disorders and blindness, cardiomyopathies (including hypertrophic cardiomyopathy), endomyocardial fibrosis and other myocardial disorders.
- Drug interactions: 100 interactions were identified in total. Examples from the first 20 reviewed:
- Major: loperamide, triamcinolone, budesonide, chlorpropamide.
- Moderate: famotidine, rabeprazole, omeprazole, hydrocortisone, dexamethasone, betamethasone, pioglitazone, alosetron, aprepitant, bisacodyl, clarithromycin.
- Minor: amphotericin B, cimetidine.
- TB-specific concern: voriconazole inhibits CYP3A4, CYP2C19 and CYP2C9, and rifamycins are potent inducers that markedly reduce voriconazole exposure. Co-administration with TB regimens is therefore a practical problem.
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.